{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:06:49Z","timestamp":1747181209064,"version":"3.40.5"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"28","license":[{"start":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:00:00Z","timestamp":1689292800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,14]]},"abstract":"<jats:p>Cervical squamous cell carcinoma (CSCC) is the most common histological type of cervical cancer (CC). And mCSCC is the end stage of CSCC. The aim of this study was to develop prognostic nomograms that provide better predictions for overall survival (OS) and cancer-specific survival (CSS) in mCSCC patients. Data from patients with initially diagnosed mCSCC were extracted from the Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2015. The nomograms for OS and CSS were constructed based on Cox regression analysis. The validation of the newly established nomograms was evaluated by concordance index (C-index), calibration curves, and decision curve analyses (DCAs). A total of 2198 patients with mCSCC were included and randomly split into training (n\u2005=\u20051539) and validation (n\u2005=\u2005659) cohorts in a 7:3 ratio. Multivariate analyses revealed that the prognostic variables significantly related to the OS and CSS were marital status, T stage, brain metastasis, lung metastasis, tumor size, number of positive lymph nodes, chemotherapy, and radiotherapy. The nomograms were constructed based on these factors. The C-index value of the nomograms for predicting OS and CSS was 0.714 and 0.683, respectively. The calibration curves of the nomograms showed good consistency between nomogram prediction and actual survival for both OS and CSS, and the DCAs showed great clinical usefulness of the nomograms. The mCSCC patients were classified into low- and high-risk groups based on the scores from the nomograms. In the validation cohort, mCSCC patients with low-risk had much higher OS and CSS than those with high-risk. We constructed nomograms for predicting the OS and CSS of patients with initially diagnosed mCSCC. Our models had satisfactory predictive performance and could be useful in survival prediction for mCSCC.<\/jats:p>","DOI":"10.1097\/md.0000000000034313","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T16:25:55Z","timestamp":1689697555000},"page":"e34313","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic models for predicting overall and cancer-specific survival of patients with initially diagnosed metastatic cervical squamous cell carcinoma: A study based on SEER database"],"prefix":"10.1097","volume":"102","author":[{"given":"Ruilin","family":"Ding","sequence":"first","affiliation":[{"name":"Institute of Drug Clinical Trial\/GCP Center, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8018-6711","authenticated-orcid":false,"given":"Zhou","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First People\u2019s Hospital of Mianyang, Sichuan Mianyang 404 Hospital, Mianyang, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Third People\u2019s Hospital of Mianyang, Mianyang, Sichuan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Longxia","family":"Chen","sequence":"additional","affiliation":[{"name":"Institute of Drug Clinical Trial\/GCP Center, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1042663","DOI":"10.3389\/fcimb.2022.1042663","article-title":"A systematic assessment of stress insomnia as the high-risk factor for cervical cancer and interplay of cervicovaginal microbiome.","volume":"12","author":"Rai","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"102225","DOI":"10.1016\/j.ctrv.2021.102225","article-title":"Exploiting somatic alterations as therapeutic targets in advanced and metastatic cervical cancer.","volume":"98","author":"Crowley","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"R3-20250504","first-page":"620","article-title":"Development and validation of a SEER-based prognostic nomogram for cervical cancer patients below the age of 45 years.","volume":"21","author":"Liu","year":"2021","journal-title":"Bosn J Basic Med Sci"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"961678","DOI":"10.3389\/fonc.2022.961678","article-title":"Nomogram models for the prognosis of cervical cancer: a SEER-based study.","volume":"12","author":"Jiang","year":"2022","journal-title":"Front Oncol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"e042364","DOI":"10.1136\/bmjopen-2020-042364","article-title":"Role of locoregional surgery in treating FIGO 2009 stage IVB cervical cancer patients: a population-based study.","volume":"11","author":"Wang","year":"2021","journal-title":"BMJ Open"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0140-6736(18)32470-X","article-title":"Cervical cancer.","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/S1470-2045(14)71116-7","article-title":"Nomograms in oncology: more than meets the eye.","volume":"16","author":"Balachandran","year":"2015","journal-title":"Lancet Oncol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"651975","DOI":"10.3389\/fonc.2021.651975","article-title":"prognostic model for predicting overall and cancer-specific survival among patients with cervical squamous cell carcinoma: a SEER based study.","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"293","DOI":"10.21037\/atm-20-6201","article-title":"Development and validation of a novel nomogram to predict cancer-specific survival in patients with uterine cervical adenocarcinoma.","volume":"9","author":"Ni","year":"2021","journal-title":"Ann Transl Med"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","article-title":"X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization.","volume":"10","author":"Camp","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1158\/1078-0432.CCR-07-4713","article-title":"Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature.","volume":"14","author":"Shariat","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.3389\/fonc.2019.01106","article-title":"Score for the overall survival probability of patients with first-diagnosed distantly metastatic cervical cancer: a novel nomogram-based risk assessment system.","volume":"9","author":"Zhang","year":"2019","journal-title":"Front Oncol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"693567","DOI":"10.3389\/fmed.2021.693567","article-title":"A nomogram-based risk classification system predicting the overall survival of patients with newly diagnosed stage IVB cervix uteri carcinoma.","volume":"8","author":"Yu","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.3802\/jgo.2016.27.e43","article-title":"Advances in diagnosis and treatment of metastatic cervical cancer.","volume":"27","author":"Li","year":"2016","journal-title":"J Gynecol Oncol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s11060-022-04082-9","article-title":"Prognostic factors for brain metastasis in women presenting cervical cancer.","volume":"159","author":"de Brito Rangel","year":"2022","journal-title":"J Neurooncol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.3904\/kjim.2018.051","article-title":"The prognostic factors influencing overall survival in uterine cervical cancer with brain metastasis.","volume":"34","author":"Kim","year":"2019","journal-title":"Korean J Intern Med"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"e24480","DOI":"10.1097\/MD.0000000000024480","article-title":"Analysis of related risk factors of lung metastasis after laparoscopic radical hysterectomy of cervical cancer.","volume":"100","author":"Henglian","year":"2021","journal-title":"Medicine (Baltim)"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ijrobp.2017.03.029","article-title":"Prognostic importance of the site of recurrence in patients with metastatic recurrent cervical cancer.","volume":"98","author":"Kim","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"7759","DOI":"10.2147\/CMAR.S203037","article-title":"Impact of sites versus number of metastases on survival of patients with organ metastasis from newly diagnosed cervical cancer.","volume":"11","author":"Yin","year":"2019","journal-title":"Cancer Manag Res"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"293","DOI":"10.4103\/ijmr.IJMR_4454_20","article-title":"Updates on systemic therapy for cervical cancer.","volume":"154","author":"Gopu","year":"2021","journal-title":"Indian J Med Res"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fonc.2012.00181","article-title":"Phase II clinical trial of robotic stereotactic body radiosurgery for metastatic gynecologic malignancies.","volume":"2","author":"Kunos","year":"2012","journal-title":"Front Oncol"},{"key":"R22-20250504","first-page":"1033","article-title":"Radiation therapy for patients with bone metastasis from uterine cervical cancer: its role and optimal radiation regimen for palliative care.","volume":"38","author":"Hata","year":"2018","journal-title":"Anticancer Res"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1097\/IGC.0000000000001313","article-title":"Radiotherapy improves the survival of patients with metastatic cervical cancer: a propensity-matched analysis of SEER database.","volume":"28","author":"Huang","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13014-019-1297-x","article-title":"Efficacy of radical doses of pelvic radiotherapy for primary tumor treatment in patients with newly diagnosed organ metastatic cervical cancer.","volume":"14","author":"Yin","year":"2019","journal-title":"Radiat Oncol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.2217\/fon-2019-0029","article-title":"Nomograms for predicting the survival rate for cervical cancer patients who undergo radiation therapy: a SEER analysis.","volume":"15","author":"Yang","year":"2019","journal-title":"Future Oncol"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study.","volume":"37","author":"Chung","year":"2019","journal-title":"J Clin Oncol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer.","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034313","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T01:20:47Z","timestamp":1746321647000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,14]]},"references-count":27,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000034313","relation":{},"ISSN":["0025-7974"],"issn-type":[{"type":"print","value":"0025-7974"}],"subject":[],"published":{"date-parts":[[2023,7,14]]}}}